Investors

Growing Shareholder Value

Press Releases

Study Finds 84% Survival Rate in Patients in Cardiogenic Shock and Other Challenging Cardiac Conditions with the New Impella 5.5 with SmartAssist

Jul 01, 2020
Read More
Additional Formats
PDF Version

Abiomed Launches Virtual Physician Education Program, CAMP PCI, to Improve High-Risk PCI Patient Outcomes

Jun 16, 2020
Read More
Additional Formats
PDF Version

Abiomed Appoints New Chief Medical Officer Charles Simonton, M.D.

Jun 15, 2020
Read More
Additional Formats
PDF Version

FDA Approves Abiomed’s First-in-Human Trial of Impella ECP, World’s Smallest Heart Pump

Jun 05, 2020
Read More
Additional Formats
PDF Version

Abiomed to Hold Fireside Chat at the William Blair 40th Annual Growth Stock Conference

Jun 03, 2020
Read More
Additional Formats
PDF Version

FDA Issues Emergency Use Authorization for Impella RP as Therapy for COVID-19 Patients with Right Heart Failure

Jun 01, 2020
Read More
Additional Formats
PDF Version

Abiomed to Hold Fireside Chat at Jefferies Virtual Healthcare Conference

May 27, 2020
Read More
Additional Formats
PDF Version

Abiomed to Host Virtual Clinical Data and Innovation Day

May 20, 2020
Read More
Additional Formats
PDF Version

PROTECT III Study Shows Placing Impella Prior to High-Risk PCI is Associated with Lower Mortality Compared to Bailout PCI

May 19, 2020
Read More
Additional Formats
PDF Version

Abiomed Announces Q4 FY 2020 Revenue of $207 Million and 28.1% Operating Margin

Apr 30, 2020
Read More
Additional Formats
PDF Version
View all